Loading the player...


INFO:

EASD 24 - Dr Phyo Htoo (Harvard Medical School, Boston, MA, US) joins us to discuss a study investigating the comparative effectiveness of empagliflozin and glucagon-like peptide-1 receptor agonists in combination as compared to either medication alone in patients with type 2 diabetes.

EASD 24: Comparative Effectiveness of Empagliflozin and GLP1s in the US | Radcliffe Cardiology